

CITATION REPORT

List of articles citing

Comparing the cost-effectiveness of rituximab maintenance and radioimmunotherapy consolidation versus observation following first-line therapy in patients with follicular lymphoma

DOI: 10.1016/j.jval.2014.12.017
Value in Health, 2015, 18, 189-97.

Source: <https://exaly.com/paper-pdf/62139560/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
28	Maintenance rituximab and radioimmunotherapy cost effective. <i>Pharmacoeconomics & Outcomes News</i> , 2015 , 724, 16-16	0.1	
27	Follicular lymphoma: first-line treatment without chemotherapy for follicular lymphoma. <i>Current Treatment Options in Oncology</i> , 2015 , 16, 32	5.4	7
26	Next-generation prognostic assessment for diffuse large B-cell lymphoma. <i>Future Oncology</i> , 2015 , 11, 2443-57	3.6	7
25	Systemic Front Line Therapy of Follicular Lymphoma: When, to Whom and How. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2016 , 8, e2016062	3.2	3
24	Zevalin(®) (ibritumomab tiuxetan): After more than a decade of treatment experience, what have we learned?. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 105, 5-17	7	58
23	Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States. <i>Journal of Clinical Oncology</i> , 2017 , 35, 166-174	2.2	94
22	Unmet needs in the first-line treatment of follicular lymphoma. <i>Annals of Oncology</i> , 2017 , 28, 2094-2106	10.3	26
21	Whither Radioimmunotherapy: To Be or Not To Be?. <i>Cancer Research</i> , 2017 , 77, 2191-2196	10.1	47
20	Pros and cons of rituximab maintenance in follicular lymphoma. <i>Cancer Treatment Reviews</i> , 2017 , 58, 34-40	14.4	7
19	Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience. <i>Advances in Therapy</i> , 2017 , 34, 2232-2273	4.1	227
18	Rituximab: a benchmark in the development of chemotherapy-free treatment strategies for follicular lymphomas. <i>Annals of Oncology</i> , 2018 , 29, 332-340	10.3	12
17	A Generic Model for Follicular Lymphoma: Predicting Cost, Life Expectancy, and Quality-Adjusted-Life-Year Using UK Population-Based Observational Data. <i>Value in Health</i> , 2018 , 21, 1176-1185	3.3	11
16	Y-ibritumomab-tiuxetan as a therapeutic alternative for follicular lymphoma (FL): A single-center experience. <i>European Journal of Haematology</i> , 2018 , 101, 514-521	3.8	2
15	Economic burden and treatment patterns for patients with diffuse large B-cell lymphoma and follicular lymphoma in the USA. <i>Journal of Comparative Effectiveness Research</i> , 2019 , 8, 393-402	2.1	8
14	Obinutuzumab plus chemotherapy followed by obinutuzumab monotherapy is cost-effective vs. rituximab plus chemotherapy followed by rituximab monotherapy for previously untreated follicular lymphoma patients in the United States. <i>Leukemia and Lymphoma</i> , 2019 , 60, 1668-1676	1.9	5
13	Evaluating Ac and Lu Radioimmunoconjugates against Antibody-Drug Conjugates for Small-Cell Lung Cancer. <i>Molecular Pharmaceutics</i> , 2020 , 17, 4270-4279	5.6	7
12	Cost-effectiveness analysis of cabazitaxel for metastatic castration resistant prostate cancer after docetaxel and androgen-signaling-targeted inhibitor resistance. <i>BMC Cancer</i> , 2021 , 21, 35	4.8	3

11	Adding Enzalutamide to First-Line Treatment for Metastatic Hormone-Sensitive Prostate Cancer: A Cost-Effectiveness Analysis. <i>Frontiers in Public Health</i> , 2021 , 9, 608375	6	1
10	The cost of chemotherapy administration: a systematic review and meta-analysis. <i>European Journal of Health Economics</i> , 2021 , 22, 605-620	3.6	1
9	Global Market of Monoclonal Antibodies: Sales, Prices, Demand. <i>Vestnik of the Plekhanov Russian University of Economics</i> , 2021 , 18, 64-76	0.4	
8	Cost-effectiveness and drug wastage of immunotherapeutic agents for hematologic malignancies: a systematic review. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021 , 21, 923-941	2.2	
7	Lifetime Costs for Treated Follicular Lymphoma Patients in the US. <i>Pharmacoeconomics</i> , 2021 , 39, 1163-1183	1.8	1
6	Positron-emission tomography-based staging is cost-effective in early-stage follicular lymphoma. <i>Journal of Nuclear Medicine</i> , 2021 ,	8.9	1
5	90 Y-ibritumomab tiuxetan: a nearly forgotten opportunity. <i>Oncotarget</i> , 2016 , 7, 7597-609	3.3	25
4	Theranostics of Hematologic Disorders. 2022 , 359-432		
3	90Y-ibritumomab tiuxetan in B-cell non-Hodgkin lymphomas: Real-world data from the United Arab Emirates. <i>Advances in Radiation Oncology</i> , 2021 , 100882	3.3	
2	Atezolizumab with chemotherapy in first-line treatment for metastatic urothelial cancer: a cost-effectiveness analysis. 2022 , 11, 1021-1030		0
1	Yttrium-90 Ibritumomab Tiuxetan is Cost-Effective Compared to Bendamustine+Rituximab in Low-grade Lymphomas. 2023 ,		0